Dakshidin Corporation announced that it had signed a Letter of Intent for a worldwide exclusive licensing agreement with GenBio. The agreement is for the exclusive rights to manufacture and distribute an entirely new product based on clinical research of a unique and proprietary superfood that GenBio has carried out over the last five years, infused with Dakshidin’s proprietary CBD formulas resulting in the only product of its kind on the market.